Roche (RHHBY) announced that it had received FDA approval for Kadcyla in patients with early-stage breast cancer. This is a good win for both the company and the patients. For the company it helps to boost the possible revenue for Kadcyla. For patients, it gives them a better opportunity to prevent breast cancer recurrence. It is imperative that patients obtain a new treatment option in this setting, because the risk of recurrence after neoadjuvant therapy remains high.
FDA Approval For Kadcyla Could Change Lives
The FDA specifically approved Kadcyla for adjuvant treatment of